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Objective: The purpose of this study was to describe the patterns of relapse in uterine
cancer (UC) and the role of surgery in the recurrent setting.
Methods: We describe surgical and clinical outcomes of all patients who underwent
surgery for recurrent UC in a gynecological oncology tertiary referral center betweenMay 1,
2013, and April 30, 2016. Progression-free survival and overall survival were estimated
using Kaplan-Meier methods with the surgery at relapse being the starting point.
Results: We evaluated 15 patients with a median age of 66 years. The predominant histology
was the endometrioid variant (n = 11; 73.3%). The median interval between the end of previous
treatment and relapse surgery was 24 months (range, 8Y164). Locoregional pelvic recurrences
were themost common type of recurrence (n =13; 86.7%)with the para-aortic lymph node space
being themost commonly affected extrapelvic site (13%). Patients predominantly presentedwith
amultifocal pattern of relapse (n = 10; 66.7%) requiringmultivisceral resections such as bowel
(n = 7; 46.6%) and/or bladder/ureteric resections (n = 8; 53.3%) to achieve complete tumor
clearance. All patients were operated tumor free with a 30-day major morbidity and mortality
rate of 6.7% and 0%, respectively. Five patients (33.3%) received postoperative chemotherapy
or radiotherapy. Five patients (33.3%) relapsed, and 3 died within a mean follow-up of
12.4 months (95% confidence interval [CI], 6.5Y18.2). Two of those patients had a sarcoma.
Mean progression-free survival and overall survival for the entire cohort postrelapse surgery
was 21.7 months (95%CI, 13.9Y29.5) and 26.0 months (95%CI, 18.4Y33.7), respectively.
Survival was significantly worse in patients with nonendometrioid histology (P G 0.0001).
Conclusions: Surgery for UC relapse seems feasible with acceptable morbidity and high
complete resection rates despite the multifocal patterns of relapse in a selected group of
patients in a reference center for gynecological cancers. Larger scale studies are warranted to
establish the value of surgery at relapse for UC.
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U terine cancer (UC) is the fourth most common cancer inEurope for women, with around 9022 new cases diag-
nosed in 2013 in the United Kingdom.1 The UC tends to have
a generally good overall prognosis, because more than 70% of
the cases will have a favorable histology and will present at an
early stage.2 Surgery is considered the gold standard approach
at initial diagnosis. Radiation and/or chemotherapy may follow
surgery as adjuvant treatment in the presence of adverse risk
factors (eg, positive lymph nodes (LN) status, lymphovascular
space invasion (LVSI), and advanced stage) or can be the primary
treatment choice in more advanced and metastatic disease.2Y5
Recurrent disease represents more aggressive tumor bi-
ology and prognosis, depending on the site and type of relapse,
locoregional or distant. In particular, distant metastases in the
liver and lung represent the most frequent causes of death in
these patients.2,3 Relapses are commonly treated with radio-
therapy and/or chemotherapy but over the past years, there has
been a rising trend toward a cytoreductive surgical approach in
highly selected patients, potentially consolidated with adjuvant
chemotherapy or radiotherapy, after the paradigm of manage-
ment of ovarian cancer relapse.6Y8 However, surgical morbidity
needs to be carefully balanced against survival benefit, and at
present, the overall experience of this approach is limited. We
present here the surgical and clinical outcome of surgery after
UC relapse in a large tertiary referral center over a period of
3 years.
MATERIALS AND METHODS
BetweenMay 2013 andApril 2016, all consecutive patients
undergoing surgery because of UC relapse in the West London
Gynecological Cancer Centre (Imperial College Healthcare
NHS Trust, London) were identified, and data were collected
from the institutional tumor registry database after local insti-
tutional board approval. Histopathological, surgical, and clin-
ical datawere retrieved from the medical records and the tumor
registry retrospectively.
Inclusion criteria were patients’ good performance status
less than 2, seemingly resectable disease as assessed by a
specialized multidisciplinary team (MDT), and patient willing
to undergo further surgery after informed consent. The exclu-
sion criteriawere poor performance status of 2 or more, serious
comorbidities that would significantly increase surgical risk,
multifocal unresectable disease, and presence of distant unresec-
table metastases, that is chest, bones, and brain. We did not set
any limitations to number or type of previous treatments.
Diagnosis of recurrence was made at routine follow-up
on clinical examination and subsequent imaging (computed
tomography, magnetic resonance imaging, and ultrasound),
with most recurrences being asymptomatic.
All patientswith pelvic or abdominal recurrence underwent
surgery via laparotomy combined with vaginal approach if
necessary. In cases of solitary exophytic vaginal recurrence,
these were resected vaginally. We did not have in our center the
possibility to perform intraoperative radiation therapy so it was
not considered as an option.
Indication for surgery was defined as apparently resect-
able diseasewithin anMDTsetting based onpatterns of relapse,
previous treatments, patients’ comorbidities, symptoms, and
preferences. Patients with multifocal unresectable distant me-
tastases in organ parenchyma, large amounts of ascites, or
pleural effusions were not considered for surgery.
Adjuvant postoperative treatment dependedon the amount
of residual disease, the intraoperative findings, the histological
subtype, as well as the previous lines and type of treatment.
TABLE 1. Characteristics of patients with recurrent UC
selected for surgery
Variables Total
Age, median (range), y 66 (33Y83)
Body mass index, median (range), kg/m2 27.7 (24.8Y37.5)
Ethnicity, n (%)
White 8 (53.3)
Black 2 (13.3)
Asian/Indian 5 (33.4)
FIGO stage at initial diagnosis, n (%)
I 9 (60)
II 1 (6.6)
III 5 (33.4)
Histology, n (%)
Endometrioid 11 (73.3)
Serous 2 (13.3)
Endometrial stromal sarcoma 1 (6.6)
Leiomyosarcoma 1 (6.6)
Grading
G1 V
G2 8 (53.3)
G3 7 (46.7)
LVSI, n (%) 9 (60)
Previous treatment
Surgery 7 (46.6)
Surgery plus CT 2 (13.3)
Surgery plus RT 4 (26.6)
Surgery plus combined CTRT 1 (6.6)
RT plus CT only 1 (6.6)
Sites of recurrence, n (%)
Single site 5 (33.3)
Multifocal 10 (66.7)
Sites of recurrence, n (%)
Vagina 13 (86.7)
Pelvis 10 (66.7)
Bladder 9 (60)
Rectum 9 (60)
Peritoneum 5 (33.4)
Pelvic nodes 2 (13.3)
Para-aortic nodes 2 (13.3)
Small bowel 2 (13.3)
CT indicates chemotherapy; RT, radiotherapy.
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Specific indications were the presence of multifocal peritoneal
relapse (chemotherapy), extensive LVSI in bulky localized dis-
ease, and positive LN status.
Statistics
Interval data were analyzed using the Mann-Whitney U
test. Nominal data were evaluated using the W2 test or Fisher
exact test when appropriate. Disease-free interval was cal-
culated from the end of previous treatment to the time of
surgery at relapse. Progression-free survival (PFS) and overall
survival (OS) were calculated from the date of relapse surgery
to clinical diagnosis of progression and death, respectively.
Survival was estimated using Kaplan-Meier methods. Pa-
rameters are expressed as median and range when achievable
or, alternatively, as mean T SD and 95% confidence interval
(CI). All statistical tests were performed using SPSS statistical
software program (SPSS 20.0 Inc, Chicago, Ill).
RESULTS
A total of 15 patients were identified within the 3-year
period from May 2013 to April 2016. The patients’ median
age at relapse surgery was 66 years (range, 33Y83 years). The
median body mass index was 27.7 kg/m2 (range, 24.8Y37.5
kg/m2). The International Federation of Gynecology and
Obstetrics (FIGO) stage at initial diagnosis was I, II, and III in
60%, 6.6%, and 33.4% of the patients, as per the new FIGO
classification, respectively.9 A total of 11 patients (73.3%)
had endometrioid histology; 2 patients (13.3%) had serous
histology; and 2 patients (13.3%) had uterine sarcoma, 1 with
stromal sarcoma and the other with leiomyosarcoma.
Treatment at initial diagnosis was by abdominal (n = 12)
or laparoscopic (n = 2) hysterectomy plus bilateral salpingo-
oophorectomy. Pelvic and para-aortic lymphadenectomy was
performed in only 1 of those patients. Just 1 patient received
concomitant chemoradiation instead of surgery because of
advanced stage of disease (stage III). Patient-related and tumor-
related characteristics are presented in Table 1. A total of 7
patients (46.7%) had received postoperative adjuvant treatment
with radiotherapy and/or chemotherapy with carboplatin and
paclitaxel at initial diagnosis. As adjuvant radiation treatment,
4 patients (26.6%) had undergone vaginal vault brachytherapy,
whereas just 1 patient (6.6%) had undergone whole pelvic
irradiation.
Recurrent disease was symptomatic in only 3 patients
(26.6%)with vaginal bleeding (n= 2) or abdominal pain (n= 1).
The rest of the patients were diagnosed at examination on
follow-up.
Median disease-free interval between surgery at relapse
and the end of previous treatment was 24 months (range,
8Y164). A total of 5 patients (33.3%) recurred at a single site,
whereas the remaining patients (66.7%) recurred multifocally
within the abdominal and retroperitoneal cavity. Of the 5 pa-
tients with single site relapse, 2 patients (13.3%) had isolated
para-aortic lymph nodal recurrences, and 3 (20%) had an iso-
lated vaginal recurrence that could be completely resected with
awide local vaginal excision. Four of 5 patientswho recurred at
a single site had endometrioid histology, whereas the 1 patient
with the para-aortic LN single recurrence had a serous histol-
ogy. The types of relapse are summarized in Table 1.
TABLE 2. Perioperative and operative outcomes
Variables Total
Operation time, median (range), min 225 (21Y370)
Estimated blood loss, median (range), mL 200 (10Y500)
Complete tumor resection achieved, n (%) 15 (100)
Procedures performed, n (%)
Pelvic peritoneal stripping 9 (60)
Partial or total colpectomy 13 (86.7)
Pelvic LND 2 (13.3)
Para-aortic LND 2 (13.3)
Bladder resection
Partial 5 (33.4)
Complete (anterior exenteration) 3 (20)
Rectal resection 3 (20)
Ureteric resection and
ureteroneocystostomy
4 (26.6)
Stoma formation (ileostomy/colostomy) 3 (20)
Ileal conduit 3 (20)
Large bowel resection 3 (20)
Small bowel resection 4 (26.6)
Primary bowel anastomosis
Large bowel 3 (20)
Small bowel 4 (26.6)
TABLE 3. Patterns of further relapses after surgery for
UC relapse
Variables Total
Mean disease-free interval ever since
secondary surgery, mean (SD)
12.4 (10.5)
No. patients experiencing II relapse, n (%) 5 (33.3)
Type of relapse, n (%)
None 10 (66.7)
Locoregional 3 (20)
Distant 2 (13.3)
Site of relapse, n (%)
Diffuse peritoneal carcinomatosis disease 2 (40)
Central pelvis/vaginal vault 3 (60)
Lateral pelvic sidewall 1 (20)
Pelvic lymph nodes 1 (20)
Lungs 1 (20)
Liver 2 (40)
Multiple recurrences, n (%) 2 (40)
Treatment of II relapses, n (%)
Chemotherapy 4 (80)
Palliative care 1 (20)
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Complete tumor resection was achieved in all 15 pa-
tients (100%). Three patients (20%) underwent a total exen-
teration; all 3 of them had undergone previous whole pelvic
irradiation. Details of the types of resections are presented in
Table 2. Seven patients (46.6%) underwent a bowel resection,
and 8 patients (53.3%) underwent a ureteric and/or bladder
resection. All patients, apart from the 3 who underwent ex-
enterations, received a primary bowel and/or ureteric anas-
tomosis, without stoma formation.
Median operative time was 225 minutes (range,
21Y370 minutes), and median blood loss was 300 mL (range,
100Y600 mL). Eight patients (53.3%) underwent a periop-
erative blood transfusion. Median postoperative hospitali-
zation was 5 days (range, 2Y30 days). Major postoperative
complications according to Clavien-Dindo classification
system10 were observed in only 1 patient (6.7%) who de-
veloped a ureteric fistula in the ileal conduit anastomosis
after exenteration. This was managed conservatively with
FIGURE 1. A, The PFS and OS after surgery for US relapse (n = 15). B, The PFS and OS in sarcomas and
nonsarcomatous histotypes.
TABLE 4. Cytoreductive surgery in recurrent uterine cancers: literature review
Author Type of Study No. Patients
Definition of Optimal
Cytoreduction Optimal Cytoreduction, n (%)
Scarabelli et al, 199818 Prospective 20 No grossly visible 13 (65)
Campagnutta et al, 200419 Prospective 75 e1 cm 56 (74.5)
Awtrey et al, 200620 Retrospective 27 e2 cm 15 (55.5)
Bristow et al, 200621 Retrospective 35 No grossly visible 23 (65.7)
Ren et al, 201422 Retrospective 75 e1 cm 43 (57.3)
Turan et al, 201523 Retrospective 34 No grossly visible 24 (70.5)
Papadia et al, 20158 Retrospective 64 No grossly visible 42 (65.6)
*Nonoptimally versus optimally cyotreduced.
†Nonsurgically treated versus surgically.
‡Estimated 5-year values in nonoptimally versus optimally cytoreduced; median values not available.
NS, not specified.
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bilateral nephrostomies for 3.5 weeks. There were no post-
operative deaths within 30 days.
Five patients (33.3%) received adjuvant treatment after
relapse cytoreductive surgery. Four patients (26.7%) received
platinum-based systemic chemotherapy, and 1 patient (6.7%)
had pelvic radiotherapy as per MDT recommendation. The
others did not receive any adjuvant treatment either because
they had undergone an exenteration that is why no evidence
exists for adjuvant treatment postexenteration, or they had a
completely excised, single-site recurrence (vaginal or para-
aortic area).
After surgery for recurrence, 5 patients (33.3%) had
experienced a further recurrence after a median interval of
7 months during amean follow-up period of 12.4T 10.5months
(95% CI, 6.5Y18.2). Two of those patients had a sarcomatous
component, and they were anticipated to relapse rather soon,
as 1 patient was undergoing her fifth surgery for peritoneally
disseminated low-grade stromal sarcoma with initial diagnosis
12 years before, and the other patient had leiomyosarcoma
relapsewith severe pelvic symptoms and had failed all previous
systemic and radiotherapeutic options.
Second relapse sites were locoregional in 3 patients
(diffuse pelvic disease and pelvic lymph nodes) and distant in
2 of them (diffuse abdominal carcinomatosis in 1 patient and
pulmonary in the other). Interestingly, all patients who re-
lapsed again locally had undergone previous radiotherapy so
they could not have any further radiotherapy. Treatment after
further relapse included palliative chemotherapy in 4 pa-
tients, whereas 1 patient received best supportive care be-
cause of large disease burden. Three of the 5 patients who
relapsed died. Detailed data regarding second relapses are
shown in Table 3.
The mean PFS was 21.7 T 4.0 months (95% CI,
13.9Y29.5), and the mean OS was 26.0 T 3.9 months (95% CI,
18.4Y29.5) as shown in Figure 1A.MedianPFSwas 16months,
whereas median OS was not reached yet. If we analyze sepa-
rately the nonsarcoma and the sarcoma patients, thenmean PFS
is 25.4 T 3.9 months versus only 6.0 T 1.0 months, respectively
(PG 0.0001), andmeanOS is 31.1T 2.7months versus 8.5 T 0.5
months, respectively (P G 0.0001) (Fig. 1B).
Additional analysis and stratification according to the
presence of LVSI, advanced age older than 70 years, and sites
TABLE 5. Multivisceral surgical procedures performed: comparison between studies in the literature
Author
Total
Patients
Type of Resection, N (%)
Bowel Resection Bladder Resection
Exenterative Procedure
(Anterior or Posterior)
Small Bowel,
n (%)
Large Bowel,
n (%) Partial Complete
Scarabelli et al, 199818 20 6 (30) 5 (25) 0 0 3 (15)
Campagnutta et al, 200419 75 9 (12) 8 (11) 0 0 13 (17.5)
Awtrey et al, 200620 27 3 (11) 4 (15) 0 0 0
Bristow et al, 200621 35 5 (14.3) 7 (20) 1 (2.9) 0 0
Ren et al, 201422 75 6 (8) 19 (25) 2 (2.7) 0 0
Turan et al, 201523 34 3 (8.8) 4 (11.8) 0 0 V
Papadia et al, 20158 64 6 (9)* 7 (11)* 5 (8)
*Not further specified.
Postoperative
Deaths, n (%)
Major
Complication Rate, %
Median Follow-up After
Recurrence, mo
Median
PFS, mo
Median OS After
Recurrence, mo
Subsequent
Relapses, n (%)
2 (10) 15 15 8.1 11.8 6 (46)
6 (8) 30.7 14 13 19 (9Y53*) 43 (64.2)
0 48 24 14 35 (10Y43*) NS
0 31.4 22 18 24 (13Y28†) NS
0 12 NS 9 18 NS
0 27.3 13.5 16.5 40 (9Y53*) NS
0 17.2% NS 19Y42‡ 30Y60‡ NS
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of relapse (pelvic vs extrapelvic) have been performed but
differences in survival were not statistically significant.
DISCUSSION
Endometrial cancer is usually diagnosed early (80%
FIGO stage I), with excellent 5-year survival rates reaching
95%.11 The overall rate of recurrence across all stages and
histological subtypes is about 10% to 15% in the first 3 years
after primary diagnosis.12,13 Nevertheless, 5-year survival
rates are worse if there is locoregional spread (68%) or distant
spread (17%).12Y15
Treatment options for recurrent disseminated UC are
rather limited and prognosis can be poor depending on the
patterns of relapse. Management options depend on type of
relapse (unifocal vs multifocal), sites of relapse, and previous
treatmentmodalities. Radiotherapy still represents themainstay
in radiotherapy-naive local recurrence cases, with chemother-
apy being preferable in systemic recurrences.
With surgical advances and techniques improving over
the recent years, improved survival seems to have been as-
sociated also with more radical techniques such as pelvic
exenteration and lateral extended pelvic sidewall resection in
patientswith central or lateral pelvicwall recurrences.Debulking
surgery is therefore developing as alternative treatment option
in the recurrent setting,16,17 a concept recently reiterated by the
‘‘ESMO-ESGO-ESTROConsensusConference onEndometrial
Cancer’’ in 2016.15
However, experience of debulking surgery feasibility in
the recurrent setting is limited, and morbidity is currently not
TABLE 6. Patient-related and disease-related characteristics of women who underwent surgery for UC relapse
Patients’
No. ID
Age at
the Time
of Surgery
Histological
Subtype
Initial
Treatment (Surgery
and Adjuvant)
Time Between
Initial Diagnosis
and Surgery for
Relapse, mo Sites of Relapse
No. 1 71 Endometrioid Surgery plus adjuvant BCT 99 Multifocal in pelvis
No. 2 71 Endometrioid Surgery 30 Vaginal introitus
No. 3 66 Endometrioid Surgery 84 Vaginal introitus
No. 4 64 Endometrioid Surgery plus adjuvant RT 71 Multifocal in pelvis
No. 5 33 Endometrioid Surgery 8 Multifocal in pelvis
No. 6 83 Serous Surgery plus adjuvant BCT 16 Multifocal in pelvis
No. 7 77 Endometrioid Surgery plus adjuvant CT 18 Para-aortic lymphadenopathy
No. 8 58 Endometrioid Surgery 18 Multifocal in pelvis
No. 9 70 Endometrioid Surgery 164 Multifocal pelvis
and pelvic
lymphadenopathy
No. 10 76 Serous Surgery plus adjuvant RTCT 17 Para-aortic lymphadenopathy
No. 11 66 Endometrioid Surgery plus adjuvant BCT 23 Multifocal in pelvis
and pelvic
lymphadenopathy
No. 12 61 Endometrioid Surgery 8 Vaginal introitus
No. 13 42 Endometrioid Surgery plus adjuvant CT 24 Multifocal in pelvis
No. 14 50 Endometrial
stromal sarcoma
Surgery 93 Multifocal peritoneal
dissemination
No. 15 49 Endometrial
stromal sarcoma
CTRT 26 Multifocal in pelvis,
small, and large bowel
BCT, brachytherapy; DOD, dead of disease; NED, no evidence of disease; PD, progression of disease.
Domenici et al International Journal of Gynecological Cancer & Volume 00, Number 00, Month 2017
6 * 2017 IGCS and ESGO
Copyright © 2017 by IGCS and ESGO. Unauthorized reproduction of this article is prohibited.
well described. Patients with endometrial cancer are frequently
elderly, overweight, and affected by numerous comorbidities,
thus surgery has to be carefully planned and tailored within a
multidisciplinary setting. Additional factors such as previous
pelvic irradiationmake any future surgeryevenmore challenging
because of the loss of anatomical planes, the tissue reaction, and
impaired tissue healing, necessitating specialized expertise.
Scarabelli et al18 were the first to report in 1998 their
experience in a series of 20 women with recurrent endometrial
cancer, achieving an optimal debulking (no detectable dis-
ease) in 65% of cases. Complications occurred in 15% of pa-
tients with 46% of the patients experiencing further recurrence.
Median survival time after recurrencewas 11.8months, and the
mortality rate was 10%.
Campagnutta and colleagues19 published data on a
series of 75 patients who underwent surgery for relapsed
UC. Complete tumor resection (indicated as residual disease
G1 cm) was achieved in 74.5% of patients, with a complication
rate of 30.7% (n = 41). Median survival after recurrence was
19 months with a significant difference between patients
undergoing suboptimal and optimal cytoreduction (PG 0.05).
In this series, a postoperative mortality of 8% was observed.
In 2006, Awtrey et al20 reported a series of 27 surgical
procedures in patients with recurrent endometrial cancer.
Residual tumor that is less than or equal to 2 cm (indicated in
the paper as optimal cytoreduction following Gynecologic
Oncology Group 12220 criteria) was obtained in 56% of pa-
tients. Also in this article, median postrecurrence survival time
was considerably longer in patients with ‘‘optimal’’ compared
with nonoptimal residual disease, even though 2 cm residual
tumor would not nowadays be considered as optimal (43 vs 10
months; P G 0.01).
In the US, Bristow et al21 evaluated the outcomes of 35
patients with relapse who underwent surgery compared with
Surgical Procedures
Performed
Time of
Follow-up, mo
Postoperative
Complications
Second Relapse Sites
and Time of Relapse
Status at Last
Follow-up
Partial colpectomy, anterior rectal
resection with end to end anastomosis,
and partial bladder resection
34 None None NED
Local vaginal excision 28 None None NED
Local vaginal excision 28 None None NED
Total exenteration 5 None Massive
intra-abdominal
DOD
Partial colpectomy, bladder partial
resection, and pelvic
peritoneal stripping
23 None None NED
Partial colpectomy, bladder partial
resection, and pelvic
peritoneal stripping
16 None Pelvic PD
Para-aortic LND 6 None None NED
Total exenteration 14 None Pelvic PD
Partial colpectomy, anterior rectal
resection with end to end anastomosis,
and peritoneal stripping, pelvic LND
1 None None NED
Para-aortic LND 8 None None NED
Partial colpectomy, bladder partial
resection, pelvic LND, and
peritoneal stripping
6 None None NED
Local vaginal excision 4 None None NED
Partial colpectomy, bladder partial
resection, anterior rectal resection with
end to end anastomosis, and pelvic
peritoneal stripping
1 None None NED
Peritoneal stripping pelvis, paracolic,
small bowel resection, and anastomosis
5 None Massive abdominal
and lungs
DOD
Total exenteration 7 Ureteric fistula in the ileal
conduit anastomosis
Pelvis and nodes DOD
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patients not treated surgically. Optimal cytoreduction (no
macroscopic residual disease) was attained in 66% of cases.
Complications were observed in 31.4% of cases. Median sur-
vival time after relapse was 24 months, and it was significantly
longer in patients after surgical treatment than in patients treated
nonsurgically (28 vs 13 months; P G 0.0001). Again, residual
disease was recognized as a predictor of survival.
Similar results were reported by a Chinese group, eval-
uating 75 Chinese patients with recurrent endometrial cancer
and obtaining ‘‘optimal cytoreduction’’ (residual disease e1 cm)
in 57.3% of the patients.22 The complication rate was 12%, and
the median survival was 18 months.
More recently, Papadia and colleagues8 described the
outcomes obtained with secondary cytoreductive surgery in
64 recurrent endometrial cancer patients, achieving optimal
debulking in 65.6% of them. The complication rate was
17.2%. The median survival time was considerably worse in
suboptimally cytoreduced patients, also in this series (estimated
5-year OS, 30% vs 60%; P = 0.01).
In our series, complete resection, interpreted as novisible
residual tumor, was obtained in all casesmost probably because
of careful patient selection. Despite the complex multivisceral
resection techniques, major morbidity was low at 6%, which
again may be attributed to a favorable patient cohort with good
performance status and no serious comorbidities. Survival after
recurrence was satisfactory compared with other studies8,18Y23
with patientswith true sarcomatous histology exhibiting poorer
overall outcome. Comparisons between the studies are sum-
marized in Tables 4 and 5. Specific data about patients who
underwent surgery for UC relapse are shown in Table 6.
Achieving complete debulking is fundamental to con-
ferring a survival benefit,24,25 similar to our experience of
surgery for ovarian cancer.24Y27 Meticulous planning and
consideration of both patient-related and tumor-related fac-
tors are key to achieve a good surgical outcome.
The main limitations of this study are the small sample size
from a single United Kingdom center and the lack of short and
long term quality of life data. Considering that the surgical treat-
ment of relapsed endometrial cancer is nonstandard in the
United Kingdom, our aim was to demonstrate feasibility of this
approach in a United Kingdom/National Health Service envi-
ronment with narrow breaching times, limited theater space, and
intensive care availability and therefore a mainly nonsurgical
approach of treatment of gynecological cancer relapse.28
We could show that complex surgical procedures for
relapsed endometrial cancer can be performed safely in such an
environment, adding further evidence to the encouraging ex-
perience of surgery in this setting. Nevertheless, larger scale
multicenter international analyses or even better prospective
randomized clinical trials are warranted to establish the value
and survival benefit of surgery in recurrent endometrial cancer,
because small, single-center analyses alone are definitely not
enough to validate and establish such an approach.
Key factors would be how to identify the ideal surgical
candidate to enable a more individualized surgical approach,
and to evaluate quality of life outcomes. Multidisciplinary
and infrastructural support, effort, and expertise seem vital to
prevent unnecessary morbidity, whereas quality of life out-
comes require further evaluation.
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